BR112015021576A2 - peptídeos terapêuticos - Google Patents

peptídeos terapêuticos

Info

Publication number
BR112015021576A2
BR112015021576A2 BR112015021576A BR112015021576A BR112015021576A2 BR 112015021576 A2 BR112015021576 A2 BR 112015021576A2 BR 112015021576 A BR112015021576 A BR 112015021576A BR 112015021576 A BR112015021576 A BR 112015021576A BR 112015021576 A2 BR112015021576 A2 BR 112015021576A2
Authority
BR
Brazil
Prior art keywords
peptides
therapeutic peptides
complementarity
therapeutic
compositions
Prior art date
Application number
BR112015021576A
Other languages
English (en)
Portuguese (pt)
Inventor
Franz Bettina
Harvey Christopher
Stephen Hodi F
Dranoff Glenn
W Wucherpfennig Kai
F May Kenneth
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of BR112015021576A2 publication Critical patent/BR112015021576A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112015021576A 2013-03-15 2014-03-14 peptídeos terapêuticos BR112015021576A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792034P 2013-03-15 2013-03-15
US201361913198P 2013-12-06 2013-12-06
PCT/US2014/029348 WO2014144791A2 (en) 2013-03-15 2014-03-14 Therapeutic peptides

Publications (1)

Publication Number Publication Date
BR112015021576A2 true BR112015021576A2 (pt) 2017-10-10

Family

ID=50588904

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021576A BR112015021576A2 (pt) 2013-03-15 2014-03-14 peptídeos terapêuticos

Country Status (15)

Country Link
US (1) US10745483B2 (enExample)
EP (2) EP3666886A1 (enExample)
JP (1) JP6397886B2 (enExample)
KR (1) KR20150130462A (enExample)
CN (1) CN105142668B (enExample)
AU (1) AU2014228502A1 (enExample)
BR (1) BR112015021576A2 (enExample)
CA (1) CA2907249A1 (enExample)
EA (1) EA201591559A1 (enExample)
ES (1) ES2779398T3 (enExample)
HK (1) HK1219983A1 (enExample)
MX (1) MX2015011075A (enExample)
NZ (1) NZ629816A (enExample)
SG (1) SG11201506766PA (enExample)
WO (1) WO2014144791A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20142361A1 (es) 2011-09-30 2015-01-16 Dana Farber Cancer Inst Inc Peptidos terapeuticos
EP3666886A1 (en) 2013-03-15 2020-06-17 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
CA2932767A1 (en) 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN106687125B (zh) 2014-03-12 2021-12-14 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
CA2939006A1 (en) * 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
TN2018000187A1 (en) 2015-12-04 2019-10-04 Dana Farber Cancer Inst Inc Vaccination with mica/b alpha 3 domain for the treatment of cancer
MA43576A (fr) 2015-12-16 2018-11-14 Merck Sharp & Dohme Anticorps anti-lag3 et fragments de fixation à l'antigène
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
GB2567093A (en) 2016-07-15 2019-04-03 Viracta Therapeutics Inc Histone deacetylase inhibitors for use in immunotherapy
JP2019535250A (ja) * 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
US20210101980A1 (en) 2017-03-31 2021-04-08 Bristol-Myers Squibb Company Methods of treating tumor
WO2019075468A1 (en) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company TUMOR TREATMENT METHODS
KR102761890B1 (ko) 2018-03-23 2025-02-06 브리스톨-마이어스 스큅 컴퍼니 Mica 및/또는 micb에 대한 항체 및 그의 용도
JP2021519771A (ja) 2018-03-30 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍を処置する方法
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
JP2022553643A (ja) * 2019-10-09 2022-12-26 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 細胞傷害性ｔ細胞耐性腫瘍を治療するための組成物および方法
KR20230152783A (ko) 2020-07-07 2023-11-03 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
CN113637077B (zh) * 2021-10-14 2021-12-24 尚健单抗（北京）生物技术有限公司 一种抗mica的抗体及其应用
US20250368742A1 (en) * 2022-04-08 2025-12-04 D2M Biotherapeutics Limited Anti-mica/b antibodies and uses thereof

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007054A1 (en) 1987-03-18 1988-09-22 Research Corporation Limited Complement-binding peptide
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8709290D0 (en) 1987-04-16 1987-05-20 Secretary Trade Ind Brit Precision motion slideways
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998019167A2 (en) 1996-10-29 1998-05-07 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040115198A1 (en) 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
WO2002068615A2 (en) 2001-02-28 2002-09-06 Fred Hutchinson Cancer Research Center, Inc. Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives
US6566208B2 (en) 2001-07-25 2003-05-20 Chartered Semiconductor Manufacturing Ltd. Method to form elevated source/drain using poly spacer
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7771718B2 (en) * 2002-04-22 2010-08-10 Fred Hutchinson Cancer Research Center Soluble MIC polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
AU2003234196A1 (en) 2002-04-22 2003-11-03 University Of Florida Functionalized nanoparticles and methods of use
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
KR100980065B1 (ko) 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
EP3679951A1 (en) 2003-06-27 2020-07-15 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
CN1317861C (zh) 2003-07-21 2007-05-23 中兴通讯股份有限公司 无线局域网接入点设备虚拟局域网的实现方法
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
PT1706424E (pt) 2004-01-12 2009-10-01 Applied Molecular Evolution Variantes da região fc
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
NZ554725A (en) 2004-10-25 2009-10-30 Merck & Co Inc Anti-ADDL antibodies and uses thereof
JP4884395B2 (ja) 2004-12-21 2012-02-29 アストラゼネカ エービー アンジオポエチン−２に対する抗体およびそれらの使用
US20080148432A1 (en) 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
BRPI0611766A2 (pt) 2005-06-08 2011-12-20 Dana Farber Cancer Inst Inc métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
JP2009514528A (ja) 2005-11-03 2009-04-09 フレッド ハッチンソン キャンサー リサーチ センター Ｎｋｇ２ｄ陽性ｃｄ４＋細胞による免疫応答の負の免疫調節法
DE102006009847A1 (de) 2006-03-01 2007-09-06 Sweredjuk, Robert, Dr. Verfahren von Absorbieren von Schadstoffen und Gerüchen
MX2009001412A (es) 2006-08-07 2009-04-24 Harvard College Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
US20110060120A1 (en) 2006-09-08 2011-03-10 Obeid Michel Sarkis Immunogenic treatment of cancer by peptides inducing the plasma membrane exposure of erp57
WO2008036981A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Research, Inc. Methods for treating mica-related disorders
US9492518B2 (en) 2006-10-04 2016-11-15 Dana-Farber Cancer Institute, Inc. Tumor immunity
CA3011859A1 (en) 2007-04-23 2008-10-30 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by erp5
WO2008143954A2 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2011063336A2 (en) 2009-11-20 2011-05-26 President And Fellows Of Harvard College Secondary site of antigen stimulation for therapeutic vaccination
EP2254602B1 (en) 2008-02-13 2018-11-21 President and Fellows of Harvard College Continuous cell programming devices
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8182809B1 (en) 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8207497B2 (en) 2009-05-08 2012-06-26 Ionsense, Inc. Sampling of confined spaces
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
KR101688522B1 (ko) 2009-12-15 2016-12-21 삼성전자주식회사 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
CN102911270A (zh) 2011-08-05 2013-02-06 浙江大学 一种抑制移植器官慢性排斥反应的抗体的制备及纯化方法
PE20142361A1 (es) * 2011-09-30 2015-01-16 Dana Farber Cancer Inst Inc Peptidos terapeuticos
SG11201404177PA (en) * 2012-02-07 2014-08-28 Innate Pharma Mica binding agents
EP3666886A1 (en) 2013-03-15 2020-06-17 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
US9572898B2 (en) 2013-09-09 2017-02-21 Seton Hall University Functionalized fluorine containing phthalocyanine molecules
CA2932767A1 (en) 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
CA2939006A1 (en) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
EP3145953A1 (en) 2014-05-21 2017-03-29 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies

Also Published As

Publication number Publication date
US20160046716A1 (en) 2016-02-18
AU2014228502A1 (en) 2015-08-20
US10745483B2 (en) 2020-08-18
EP2970908B1 (en) 2019-12-25
EP3666886A1 (en) 2020-06-17
CN105142668B (zh) 2018-04-27
MX2015011075A (es) 2015-10-29
NZ629816A (en) 2017-07-28
EA201591559A1 (ru) 2016-03-31
JP2016516059A (ja) 2016-06-02
KR20150130462A (ko) 2015-11-23
ES2779398T3 (es) 2020-08-17
CN105142668A (zh) 2015-12-09
SG11201506766PA (en) 2015-09-29
WO2014144791A2 (en) 2014-09-18
EP2970908A2 (en) 2016-01-20
WO2014144791A3 (en) 2014-11-27
HK1219983A1 (zh) 2017-04-21
CA2907249A1 (en) 2014-09-18
JP6397886B2 (ja) 2018-09-26

Similar Documents

Publication Publication Date Title
BR112015021576A2 (pt) peptídeos terapêuticos
BR112014007487A2 (pt) peptídeos terapêuticos
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
BR112016012358A2 (pt) peptídios terapêuticos
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
MX374785B (es) Anticuerpos anti-fgfr2iiib afucosilados.
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112014011594A2 (pt) anticorpos anti-il-36r
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
BR112019007613A2 (pt) terapia de combinação para inibição de c3
BR112015021134A2 (pt) conjugados de fármaco e anticorpo
EP3082797A4 (en) Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
BR112015029686A2 (pt) composições para o tratamento de superfícies compreendendo corantes fotocrômicos
BR112015012987A2 (pt) composições compreendendo anticorpos anti-cd38 e lenalidomida
BR112015000329A2 (pt) formulações de diclofenac
BR112015023387A2 (pt) composições lipídicas de racecodotril
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
DK3020732T3 (da) Immunoglobulin-Fc-konjugat, som bevarer immunoglobulin-Fc-fragmentets bindingsaffinitet til FcRn
EA201500363A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
BR112019005783A2 (pt) agentes de ligação monoclonal com cmet, conjugados de fármaco dos mesmos e usos dos mesmos
BR112014030755A2 (pt) composições de intensificação de culturas
BR112015023463A2 (pt) uso de sedoeptulose para prevenção ou tratamento de inflamação
BR112015023730A2 (pt) uso de sedoeptulose como suplemento nutricional
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
TH148778A (th) เปปไทด์รักษาโรค

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.